ArticleFrontiers in oncology2021
The Relationship Between Gut Microbiome Features and Chemotherapy Response in Gastrointestinal Cancer.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 3 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- The pathobiont role of Akkermansia muciniphila in colorectal cancer: a systematic review.BMC gastroenterology · 2025Pooled it
- Global prevalence of Fusobacterium nucleatum and Bacteroides fragilis in patients with colorectal cancer: an overview of case reports/case series and meta-analysis of prevalence studies.BMC gastroenterology · 2025Pooled it
- Changes in the gut microbiota of esophageal carcinoma patients based on 16S rRNA gene sequencing: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- From gut to brain: data-driven evidence suggests causal contribution of gut-microbiota to major depressive disorder in humans.Gut microbes · 2026Article
- Microbiota in pancreatic cancer: Roles in tumor initiation and progression (Review).Oncology letters · 2026Review
- Gut microbiota modulation of gastrointestinal cancers: from dysbiosis signatures to therapeutic interventions.Acta pharmacologica Sinica · 2026Review
- Microbiome-Shaped Metastatic Niches in Colorectal Cancer: Organ-Specific Patterns, Immune-Metabolic Mechanisms, and Therapeutic Translation.Microorganisms · 2026Review
- Clinical potential of the gut microbiome in oncology: a scoping review of treatment response, toxicity and biomarker development.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Gut microbiota-metabolism axis in digestive tumors: Emerging targets for novel therapies (Review).Experimental and therapeutic medicine · 2026Review
- Reprogramming Gastric Cancer Therapy: A Microbiome-Guided Approach to Precision Oncology.Current microbiology · 2026Review
- Effect of chemotherapy on gut microbiota in patients with colorectal cancer.Frontiers in microbiology · 2026Article
- The role of theFrontiers in microbiology · 2026Review
- Host-microbiome interactions in breast cancer progression and treatment response.Frontiers in medicine · 2026Review
- Gut microbiota-mediated chemotherapy resistance in colorectal cancer: mechanisms and precision interventions.Frontiers in oncology · 2026Review
- Gut microbiota as a hidden modulator of chemotherapy: implications for colorectal cancer treatment.Discover oncology · 2025Review
- The role of the gut microbiota in chemotherapy response, efficacy and toxicity: a systematic review.NPJ precision oncology · 2025Article
- Gut microbiome and gastric cancer: microbial interactions and therapeutic potential.Gut pathogens · 2025Review
- The role ofiMetaOmics · 2025Article
- Advances in 16S rRNA-Based Microbial Biomarkers for Gastric Cancer Diagnosis and Prognosis.Microbial biotechnology · 2025Review
- Microbiota and gastric cancer: from molecular mechanisms to therapeutic strategies.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe prognosis of advanced gastrointestinal cancer is poor. There are studies indicating that gut microbes might have the predictive ability to evaluate the outcome of cancer therapy, especially immunotherapy. There is limited evidence to date on the influence of microbes on chemotherapeutic response.
designIn total, 130 patients with advanced or metastatic esophageal (n=40), gastric (n=46), and colorectal cancer (n=44) were enrolled. We included 147 healthy people as controls and used 16S rRNA sequencing to analyze the fecal microbiota.
resultsSignificant differences in the abundance of fecal microbiota between patients with gastrointestinal cancer and controls were identified. The abundance of
conclusionThe gut microbiome of patients with esophageal cancer, gastric cancer, and colorectal cancer differs from those of healthy people. The abundance alteration of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.